Pierre Fabre Pharmaceuticals
Manufacturing · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
500 Plaza Dr, Secaucus, New Jersey, 0709...Revenue
$26.4 MillionIndustry
About Pierre Fabre Pharmaceuticals
Pierre Fabre Pharmaceuticals Org Chart
Is Pierre Fabre Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Pierre Fabre Pharmaceuticals launches new products
Check out if Pierre Fabre Pharmaceuticals is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Pierre Fabre Pharmaceuticals has new funding data
Earning: See what the market has to say on Pierre Fabre Pharmaceuticals recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Pierre Fabre Pharmaceuticals had a recent Job posting/layoffs
Pierre Fabre Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Pierre Fabre Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Pierre Fabre Pharmaceuticals
Recommended Actions
Find VP level buyers at Pierre Fabre Pharmaceuticals
Find more new buyers
Pierre Fabre Pharmaceuticals Tech Stack
A closer look at the technologies used by Pierre Fabre Pharmaceuticals
Most Recent Scoops
Pierre Fabre Pharmaceuticals News & Media
Pierre Fabre Pharmaceuticals Announces Type A Meeting Agreed with U.S. Food and Drug Administration (FDA) for Tabelecleucel Biologic License Application (BLA)
SECAUCUS, N.J., March 12, 2026 /PRNewswire/ -- Pierre Fabre Pharmaceuticals, Inc., announces the U.S. Food and Drug Administration (FDA) has agreed to Type A meeting for the biologic license application for tabelecleucel, an allogeneic T-cell therapy with a proposed indication for...Pierre Fabre Pharmaceuticals Submits Type A Meeting Request to U.S. Food and Drug Administration (FDA) for Tabelecleucel Biologic License Application (BLA)
SECAUCUS, N.J., March 3, 2026 /PRNewswire/ -- On March 2, 2026, Pierre Fabre Pharmaceuticals, Inc., submitted a request to the U.S. Food and Drug Administration (FDA) for a Type A meeting on the biologic license application for tabelecleucel, an allogeneic T-cell therapy with a proposed...PIERRE FABRE PHARMACEUTICALS STATEMENT REGARDING RECEIPT OF COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BIOLOGICS LICENSE APPLICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION
SECAUCUS, N.J., Jan. 12, 2026 /PRNewswire/ -- On January 9, 2026, Pierre Fabre Pharmaceuticals, Inc. received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) stating that the Agency is unable to approve the tabelecleucel Biologics License Application...
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pierre Fabre Pharmaceuticals
Pierre Fabre Pharmaceuticals is dedicated to delivering breakthrough therapies for US patient populations with high unmet needs, particularly in oncology and rare diseases. The company emphasizes innovation through partnerships with healthcare professionals and researchers, aiming to improve the lives of patients through patient-centric therapeutic... Read More